A5043335646- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Viral-associated cancers and disorders
- Cancer Mechanisms and Therapy
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Signaling Pathways in Disease
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- PI3K/AKT/mTOR signaling in cancer
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Cancer-related gene regulation
- Research on Leishmaniasis Studies
- Cutaneous lymphoproliferative disorders research
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Complement system in diseases
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Immunotherapy and Immune Responses
Kyoto Prefectural University of Medicine
2016-2025
Kyoto Prefectural University
2023
Otsu Municipal Hospital
2023
Walter and Eliza Hall Institute of Medical Research
2018-2023
The University of Melbourne
2022
Kindai University
2018
Nagoya City University
2012
Kyowa Kirin (Japan)
2012
Abstract Sarcopenia is a crucial factor in the physical fitness of elderly individuals. This study investigated prognostic values multiple parameters sarcopenia association with established factors Japanese patients diffuse large B cell lymphoma (DLBCL). As candidate indicators for sarcopenia, skeletal muscle index (SMI) (cm 2 /m ), psoas index, erector spinae visceral fat subcutaneous and to area ratio at third lumbar level were assessed by computed tomography their initial diagnosis 102...
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (PCAE-CTL) is a rare subtype of with poor prognosis. We herein report case PCAE-CTL accompanied by anti-Ma2 antibody-positive paraneoplastic encephalitis. A 33-year-old woman erythema and disturbance consciousness was diagnosed skin biopsy. Head magnetic resonance imaging revealed bilateral medial temporal lobe hyperintensity, antibody in the cerebrospinal fluid positive. She concurrent In cases brain lesions,...
Despite the oncogenic roles of serine/threonine kinase PDPK1 and its key effectors, RSK2 AKT, their activation status prognostic significance remain unexamined in B cell lymphomas (BCLs). This study evaluated phosphorylation states PDPK1, RSK2-N-terminal domain (NTKD), AKT through immunohistochemical analyses 468 biopsied samples from patients with nine subtypes MLs, including diffuse large lymphoma (DLBCL) (n = 277) follicular (FL) 121). was frequently phosphorylated most subtypes, showing...
This study retrospectively aimed to assess the real-world efficacy and safety of polatuzumab vedotin with bendamustine rituximab for relapsed/refractory diffuse large B-cell lymphoma, analyzing 72 patients within Kyoto Hematology Clinical Study Group. The median age was 77, one-third participants over 80 half having previously received three or more lines treatment. overall response rate 73.6%, including 45.8% complete response. progression-free survival (PFS) 7.6 months. Poor performance...
The use of chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies is rapidly increasing, and appropriately managing adverse events (AEs) crucial. Cytokine release syndrome (CRS) a common AE CAR-T therapy, characterized by systemic symptoms such as fever respire-circulatory failure. We present two cases with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) accompanied rare complication cervical local CRS an acute inflammatory reaction at specific site after...
Although the coronavirus disease 2019 (COVID-19) pandemic is coming to an end, it still poses a threat immunocompromised and others with underlying diseases. Especially in cases of persistent COVID-19, new mutations conferring resistance severe acute respiratory syndrome 2 (SARS-CoV-2) therapies have considerable clinical implications. We present patient who independently acquired T21I mutation 3CL protease after nirmatrelvir exposure. The one most frequent responsible for resistance....
Subcutaneous panniculitis-like T cell lymphoma (SPTL) is a rare subtype of non-Hodgkin for which definitive therapeutic strategy has not been established yet. We report case chemotherapy-resistant SPTL with hemophagocytic syndrome (HPS) was successfully treated cyclosporine A (CsA) plus methylprednisolone (mPSL), and also reviewed 11 cases CsA, previously reported in the literature. Our patient 38-year-old female SPTL. The disease progressed despite conventional chemotherapy using cytotoxic...
Multiple myeloma is a cytogenetically/molecularly heterogeneous hematologic malignancy that remains mostly incurable, and the identification of universal relevant therapeutic target molecule essential for further development strategy. Herein, we identified 3-phosphoinositide-dependent protein kinase 1 (PDPK1), serine threonine kinase, expressed active in all eleven multiple myeloma-derived cell lines examined regardless type cytogenetic abnormality, mutation state RAS FGFR3 genes, or...
Multiple myeloma is an entity of cytogenetically and genetically heterogenous plasma cell neoplasms. Despite recent improvement in the treatment outcome multiple by novel molecular-targeted chemotherapeutics, remains incurable. The identification a therapeutic target molecule which various signaling for cell-survival converge core component development new strategies against myeloma. RSK2 essential mediator ERK1/2 pathway survival proliferation. In this study, we discovered that...
Abstract Three types of chromosomal translocations, t(4;14)(p16;q32), t(14;16)(q32;q23), and t(11;14)(q13;q32), are associated with prognosis the decision making therapeutic strategy for multiple myeloma (MM). In this study, we developed a new diagnostic modality multiplex FISH in immunophenotyped cells suspension (Immunophenotyped-Suspension-Multiplex (ISM)-FISH). For ISM-FISH, first subject to immunostaining by anti-CD138 antibody and, then, hybridization four different probes genes IGH ,...
The shift of the tumour immune microenvironment to a suppressive state promotes not only development and progression disease in multiple myeloma (MM) but also resistance immunotherapy. We previously demonstrated that cells can induce monocytic myeloid-derived suppressor (M-MDSCs) from healthy peripheral blood mononuclear (PBMCs) via concomitant secretion CC motif chemokine ligand 5 (CCL5) macrophage migration inhibitory factor (MIF), an unknown mediator M-MDSC induction. This study...
Background and Purpose: Anti-CD20 monoclonal antibodies (MoAbs), rituximab (RIT), obinutuzumab (OBZ) are the central components of immunochemotherapy for B-cell lymphoma (BCL). However, these agents potentially cause depletion, resulting in impairment antibody (Ab) production. During severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, optimal prediction Ab response against anti–SARS-CoV-2 vaccination is critically important patients with BCL treated by depletion...
Abstract Many lymphoid malignancies arise from deregulated c-MYC expression in cooperation with additional genetic lesions. While many of these cooperative lesions have been discovered and their functions characterised, DNA sequence data primary patient samples suggest that more do exist. However, the nature contributions to driven lymphomagenesis not yet investigated. We identified TFAP4 as a potent suppressor lymphoma development previous genome-wide CRISPR knockout screen cells vivo [1]....
RUNX1 (previously termed AML1) is a frequent target of human leukaemia-associated gene aberrations, and it encodes the DNA-binding subunit Core-Binding Factor transcription factor complex. expression essential for initiation definitive haematopoiesis, steady-state thrombopoiesis, normal lymphocytes development. Recent studies revealed that protein arginine methyltransferase 1 (PRMT1), which accounts majority type I PRMT activity in cells, methylates two residues (R206 R210), these...
The incorporation of rituximab in immunochemotherapy has improved treatment outcomes for diffuse large B-cell lymphoma, but the prognosis some lymphomas remains dismal. Identification adverse prognostic subgroups is essential choice appropriate therapeutic strategy.We retrospectively investigated impact so-called 'double-hit' cytogenetic abnormalities, i.e. abnormalities involving c-MYC co-existing with other poor BCL2, BCL6 or BACH2, on 93 consecutive lymphoma patients.According to revised...
B-cell lymphomas (BCLs) are the most common disease entity among hematological malignancies and have various genetically molecularly distinct subtypes. In this study, we revealed that blockade of phosphoinositide-dependent kinase-1 (PDPK1), master kinase AGC kinases, induces a growth inhibition via cell cycle arrest induction apoptosis in all eight BCL-derived lines examined, including those from activated B-cell-like diffuse large lymphoma (DLBCL), double expressor DLBCL, Burkitt lymphoma,...
Abstract We investigated clinical and genetic characteristics of high-risk follicular lymphoma (FL), that lacked evidence large cell transformation at diagnosis, in the rituximab era. First, we retrospectively analysed features 100 patients with non-transformed FL were consecutively treated rituximab-containing therapies a discovery cohort. The presence either peripheral blood and/or bone involvement was associated short progression-free survival. This confirmed validation cohort 66...
Azacitidine is the first-line therapeutic option for myelodysplastic syndrome (MDS). This report describes a case of MDS in patient who developed fatal acute interstitial pneumonitis (AIP) after first seven-day course intravenous azacitidine (75 mg/m2/day) treatment. A review previous and present studies azacitidine-associated AIP suggests that may cause life-threatening during or treatment, with pyrexia commonly preceding AIP. Although non-hematologic adverse events associated are generally...